Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever.

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Abstract Text:

OBJECTIVE: Previous reports on interferon-alpha (IFN-alpha) were conflicting with respect to its efficacy in familial Mediterranean fever (FMF) refractory to colchicine treatment. We investigated the effect of IFN-alpha in patients with colchicine-resistant FMF. METHODS: In a prospective, patient self-controlled, open-label study evaluating the safety and efficacy of IFN-alpha in patients with FMF with a severe phenotype, refractory to intensified (oral plus intravenous) colchicine therapy, we advised patients to subcutaneously inject IFN-alpha, 3 million international units, at the onset of the FMF attack. Attacks not treated with IFN-alpha of the same patients and in the same sites served as control attacks. Features of each attack were recorded in a questionnaire, eventually used to compare between IFN-alpha-treated and non-treated attacks. RESULTS: Ten patients with a total of 80 attacks were recruited. Compared to 22 untreated attacks, a > 20% and > 50% reduction in the duration of the attacks was noted in 100% and 90% of the 58 IFN-alpha-treated attacks, respectively (p < 0.001 for both). The severity (degree of pain) of the IFN-alpha-treated attacks was attenuated by > 20% and > 50% in 88% and 49% of these attacks, respectively (p < 0.001 for both). The most common drug-related adverse events were chills and fatigue. CONCLUSION: Early intervention with IFN-alpha injections was associated with reduced attack length and/or severity in a substantial number of bouts, with an acceptable cost of adverse events.

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of rheumatology

VOLUME: 35

Page Numbers: 1362-5

Journal Abbreviation: J. Rheumatol.

ISSN: 0315-162X

DAY: 1

MONTH: 06

YEAR: 2008

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7501984

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever.

AFFILIATION: From the Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Rheumatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever Related Publications

• Analysis of strand transfer and template switching mechanisms of DNA gap repair by homologous recombination in Escherichiacoli: predominance of strand transfer.
• Appendectomy in familial Mediterranean fever: clinical, genetic and pathological findings.
• Biochemical analysis of UV mutagenesis in Escherichia coli by using a cell-free reaction coupled to a bioassay: identification of a DNA repair-dependent, replication-independent pathway.
• DNA repair of oxidative DNA damage in human carcinogenesis: Potential application for cancer risk assessment and prevention.
• Familial Mediterranean fever and cryptogenic cirrhosis.
• Familial Mediterranean fever gene and protection against asthma.
• Familial Mediterranean fever: clinical, molecular and management advancements.
• Interferon-alpha as a Treatment Modality for Colchicine- Resistant Familial Mediterranean Fever.
• MEFV mutations and palindromic rheumatism: Comment on the article by Cañete et al.
• Mutations in the familial Mediterranean fever gene of patients with IgA nephropathy and other forms of glomerulonephritis.
• PKCeta expression contributes to the resistance of Hodgkin's lymphoma cell lines to apoptosis.
• Reduced efficiency and increased mutagenicity of translesion DNA synthesis across a TT cyclobutane pyrimidine dimer, but not a TT 6-4 photoproduct, in human cells lacking DNA polymerase eta.
• Reduced repair of the oxidative 8-oxoguanine DNA damage and risk of head and neck cancer.
• Single-stranded DNA-binding Protein Recruits DNA Polymerase V to Primer Termini on RecA-coated DNA.
• Unique spectrum of MEFV mutations in Iranian Jewish FMF patients--clinical and demographic significance.
• [Aspirin and endoscopy]
• [ECG changes during stroke]
• [Neurogenic pulmonary edema]